Wall Street analyst estimates for Halozyme Therapeutics, Inc. (HALO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $2.25 | ||
| 2026-08-06 | $2.28 | $1.79 | +27.4% |
| 2026-05-11 | $1.60 | $1.55 | +3.2% |
| 2026-02-17 | $-0.24 | $2.15 | -111.2% |
| 2025-11-03 | $1.72 | $1.63 | +5.5% |
| 2025-08-05 | $1.54 | $1.23 | +25.2% |
| 2025-05-06 | $1.11 | $0.95 | +16.8% |
| 2025-02-18 | $1.26 | $1.17 | +7.7% |
Valuation Ratios
| P/E Ratio | 30.18 |
| Price / Book | 86.81 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.02B | $1.40B |
| Cost of Revenue | $33.2M | $31.2M | $10.1M | $45.5M | $43.4M | $81.4M | $139.3M | $192.4M | $159.4M | $305.4M |
| Gross Profit | $113.5M | $285.5M | $141.7M | $150.4M | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.09B |
| Research & Development | $150.8M | $150.6M | $150.3M | $140.8M | $34.2M | $35.7M | $66.6M | $76.4M | $79.0M | $81.5M |
| Selling, General & Admin | $45.9M | $53.8M | $60.8M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $193.4M |
| Operating Expenses | $196.7M | $204.5M | $211.1M | $218.1M | $80.0M | $86.0M | $253.3M | $299.3M | $304.4M | $274.9M |
| Operating Income | -$83.2M | $81.0M | -$69.3M | -$67.6M | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $816.3M |
| EBITDA | -$79.5M | $83.2M | -$69.3M | -$56.6M | $153.0M | $259.0M | $315.5M | $451.9M | $656.5M | $573.1M |
| Interest Expense | $20.0M | $22.0M | $18.0M | $11.6M | $20.4M | $7.5M | $16.9M | $18.8M | $18.1M | $18.1M |
| Pre-tax Income | -$101.9M | $61.6M | -$79.8M | -$72.3M | $129.3M | $248.5M | $248.9M | $348.3M | $557.1M | $466.9M |
| Income Tax | $1.2M | -$1.4M | $537000 | -$11000 | $217000 | -$154.2M | $46.8M | $66.7M | $113.0M | $150.0M |
| Net Income | -$103.0M | $63.0M | -$80.3M | -$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| EPS | $-0.81 | $0.46 | $-0.56 | $-0.50 | $0.95 | $2.86 | $1.48 | $2.13 | $3.50 | $2.64 |
| EPS (Diluted) | $-0.81 | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Shares Outstanding (Diluted) | $128.0M | $139.1M | $143.6M | $144.3M | $141.5M | $146.8M | $140.6M | $134.2M | $129.4M | $123.9M |
Price
| Price | $108.44 |
| Market Cap | $12.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks